retatrutide diabetes trial Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 New weekly diabetes jab retatrutide

The rise of FSH at menopause in response to ovarian failure has been associated with menopausal adiposity ( In an ovariectomized mouse model, an antibody (for humans and mice) to FSH (was initially found to inhibit bone resorption and stimulate bone synthesis ( via upregulating UCP1 (uncoupling protein 1) expression in both visceral and subcutaneous adipose tissues ( Although evidence that FSH is a key factor in fat accumulation is robust, this is so far applicable only to some rodent models

The cytoprotective effects of GLP-1(2836) are attenuated in the absence of sAC

Van Cauwenberghe et al

Tips for Managing Side Effects Eat smaller, more frequent meals Avoid fatty, greasy, or heavily processed foods Stay well hydrated Support your gut health with fiber and probiotics Communicate with your provider about symptom severity Important Safety Information The prescribing information includes a boxed warning about the risk of thyroid C-cell tumors, based on animal studies

Do not ice immediately before injecting, as this can increase needle entry discomfort, but post injection cold application is helpful for some people